2023
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Velez J, Karakala N, Tayebi K, Wickman T, Mohamed M, Kovacic R, Therapondos G, Kanduri S, Allegretti A, Belcher J, Regner K, Wentowski C. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. Kidney360 2023, 4: e448-e456. PMID: 36763632, PMCID: PMC10278824, DOI: 10.34067/kid.0000000000000068.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Mean arterial pressureSyndrome type 1HRS-1Baseline SCrMAP riseType 1Serum creatinineArterial pressureKidney functionDay 14Baseline mean arterial pressureMean mean arterial pressureMedian mean arterial pressureEnd-stage liver diseaseMultivariate logistic regression analysisFavorable renal outcomeOptimal MAP targetsUse of norepinephrineLogistic regression analysisGreater reductionMedian sCrNorepinephrine useVasoconstrictor therapyRenal outcomes
2011
Clinical Applications of Biomarkers for Acute Kidney Injury
Belcher JM, Edelstein CL, Parikh CR. Clinical Applications of Biomarkers for Acute Kidney Injury. American Journal Of Kidney Diseases 2011, 57: 930-940. PMID: 21411200, DOI: 10.1053/j.ajkd.2010.11.032.BooksConceptsDiagnosis of AKIAcute kidney injurySerum creatinine levelsKidney injuryCreatinine levelsIL-18Multiple novel biomarkersProspective trial designUtility of biomarkersAdequate poweringSuccessful human trialsInterleukin-18Kidney functionNovel therapiesDifferential diagnosisHuman trialsNovel biomarkersTrial designAnimal studiesTherapeutic efficacyInjuryDiagnosisEarly detectionBiomarkersPotential role